Italian Medicines Agency (AIFA) has granted operational authorisation to biotech company ReiThera to open its new production area at its pharmaceutical facility located at the Castel Romano Technopole.
Global biotechnology firm CSL has signed a strategic option and license deal with biopharmaceutical company Translational Sciences for thrombus dissolving drug candidate, TS23.
Shanghai Fosun Pharmaceutical’s member Hangzhou Celregen Therapeutics has entered into an exclusive license agreement with Japanese regenerative medicine start-up Cellusion for CLS001.
Evaxion Biotech, along with UMass Chan Medical School, has received a funding from the US National Institutes of Health (NIH) to develop a lead vaccine candidate to treat gonorrhea.
CARsgen Therapeutics has announced the start of production at its Current Good Manufacturing Practice (CGMP) manufacturing facility in North Carolina, US and released the first CAR T cells batch for clinical trials.
BioDuro-Sundia and X-Chem have collaborated to launch the DNA encoded compound library (DEL) technology services in China for the discovery of new small molecule drugs.
Kiniksa Pharmaceuticals has entered into a global license agreement with Roche and its subsidiary, Genentech, for the development and commercialisation of an investigational fully human monoclonal antibody, vixarelimab.
ViiV Healthcare and the Medicines Patent Pool (MPP) have entered into a voluntary licensing agreement to expand access to cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).
Procaps Group, an integrated LatAm healthcare and pharmaceutical conglomerate, has signed a definitive agreement to buy Grupo Somar, which includes Grupo Farmacéutico Somar and Química y Farmacia and, Gelcaps and associated entities from Advent International, a private equity investor.
Artax Biopharma is set to develop its first oral small molecule immunomodulating agent, AX-158, after it closed a $26m financing round.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.